An FDA-authorized expanded access program for an investigational therapy, offered within a personalized cognitive health practice in Leawood, Kansas.
Medically reviewed by Mark Strehlow, MD, Medical Director — September 2026
A note to you and your family
If you are reading this, you or someone you love is facing a diagnosis of Alzheimer’s disease or a related dementia, and you are weighing what to do next. You want to understand what can be done, what is real, and what is worth your time, your hope and your resources.
This page explains what the program is, what the science behind TB006 shows so far, what taking part involves, and how we will walk alongside you if you choose to begin. You will get clear, straight answers from us at every step.
What the Expanded Access Program is
Expanded access, sometimes called compassionate use, is an FDA pathway that allows people with serious illnesses to receive an investigational medicine when approved treatments have not helped and no suitable clinical trial is available. TB006, developed by TrueBinding, has been available through this pathway for Alzheimer’s disease and related dementias since June 2023.
TB006 is investigational. It is not FDA approved and remains under study. Because of that, careful safety monitoring is built into every step of the program.
How TB006 works
TB006 is a monoclonal antibody, a medicine engineered to bind a single target in the body. Its target is a protein called galectin-3, which researchers have linked to two processes that drive Alzheimer’s disease: the buildup of toxic protein aggregates in the brain, and the chronic inflammation that damages brain cells over time. By blocking galectin-3, TB006 is designed to interrupt both. It is a different approach from the amyloid-targeting therapies most families have heard about.
What the studies show so far
- Well tolerated. In clinical studies TB006 has been well tolerated, with no serious side effects linked to the treatment.
- A very low reported rate of ARIA. Several newer Alzheimer’s medicines carry a risk of brain swelling or small areas of bleeding (ARIA). Across a global safety dataset of more than 3,500 administered doses, a single non-serious ARIA-related event has been reported to date.
- Encouraging effects on cognition. In clinical studies, patients treated with TB006 showed encouraging improvements in cognition, including statistically significant results on some measures, particularly among patients with milder disease.
Because TB006 is still being studied, benefits cannot be guaranteed for any individual.
Who the program may be for
- Over age 55, with a diagnosis of Alzheimer’s disease or a related dementia
- Has tried an approved dementia medication without meaningful benefit, or cannot take one (if one has not been tried, this can usually be arranged before enrollment)
- Cannot join a clinical trial, because none is available nearby or they do not qualify
- Has a care partner who can attend each visit
- Is able to travel to our Leawood clinic for monthly treatment
A simple in-office saliva test, blood tests and a brain MRI help confirm candidacy and diagnosis. Dr. Strehlow makes the final eligibility determination. If the program is not the right fit, we will tell you directly and help point you toward other options.
What to expect, step by step
- Getting started. You reach out, we gather records from your current doctors, and we schedule a first visit.
- The screening visit. One appointment of about three hours, with your care partner present: history, examination, a brief cognitive assessment, an EKG, the Brain Gauge, and the saliva test. Bloodwork and a brain MRI follow in the next days. There is no obligation to continue.
- Confirming eligibility. Results take about two to three weeks. We then submit your enrollment request to TrueBinding for review.
- Beginning treatment. Most families can expect about five to seven weeks between the screening visit and the first infusion.
What ongoing treatment looks like
TB006 is given as an intravenous infusion roughly every 28 days. The first infusion runs at least 90 minutes; later infusions typically take one to two hours. No premedication is required.
| What we monitor | How often |
|---|---|
| Vital signs and symptom check | Every visit |
| Cognitive assessment (MMSE) | Every 3 months |
| EKG | Every 3 months |
| Brain MRI | Baseline, 6 months, 12 months, then yearly |
| Laboratory testing | Baseline, then every 6 months |
| Physical examination | Yearly |
Treatment has no fixed endpoint. It continues as long as you, your loved one and Dr. Strehlow agree it is the right course, and it can be paused or stopped at any time.
Cost
We want you to know this before you call: expanded access treatment is expensive, and it is not covered by insurance. The cost includes the medicine itself, physician and clinic fees for administering and monitoring treatment, and the exams, imaging and lab work the program requires.
- The screening visit is $750, and that fee is applied to your treatment cost if you are eligible and choose to proceed.
- Full treatment pricing is discussed at your consultation, so you can make the decision with complete information.
Why Rock Creek Wellness
Rock Creek Wellness is an approved site for the TB006 Expanded Access Program. But the reason to choose us is how we practice.
- One physician who knows you. Dr. Strehlow oversees every step personally.
- Time and attention. As a concierge clinic, we are built around unhurried visits and direct access to your care team.
- A true partnership. We treat your care partner as part of the team, because they are.
- Straight answers. We will tell you what we know, what we are still learning, and what we would do in your position.
TB006 is one part of a comprehensive approach to brain health. Learn about our Cognitive Health Protocol.
Take the first step
Call (913) 727-7700 or contact us to schedule a conversation about whether the TB006 Expanded Access Program may be right for your family.
TB006 is an investigational drug and has not been approved by the FDA. Individual results vary and benefits cannot be guaranteed. To learn more about TB006, visit TrueBinding at truebinding.com.